This press release details Abbott's financial performance for the second quarter and first half of 2025, highlighting strong sales growth driven by its diverse portfolio, particularly in Medical Devices and Established Pharmaceuticals. The report emphasizes organic sales growth by excluding the diminishing impact of COVID-19 testing-related sales, providing a clearer picture of the company's core business expansion. Key product approvals and pipeline advancements, such as a new mitral valve replacement system and a leadless pacemaker, underscore Abbott's innovation in healthcare technology. Furthermore, the company reaffirms its full-year 2025 financial projections and announces its 406th consecutive quarterly dividend, reflecting consistent shareholder returns.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related